Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer

Cancer

Volumn 110, Issue 10, 2007, Pages 2186-2190

  Patel, Pooja R ^a   Yao, James C ^a   Hess, Kenneth ^a   Schnirer, Isac ^a   Rashid, Asif ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Median survival; Metachronous metastases; Stomach neoplasms; Synchronous metastases

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; CELL DIFFERENTIATION; CHRONOLOGY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; PRIORITY JOURNAL; RECURRENT CANCER; STOMACH CANCER;

ADULT; CELL DIFFERENTIATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 36049041592     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23046     Document Type: Article

References (18)

1. Parkin DM, Bray F, Pisan P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
3. Tas F, Aykan NF, Aydiner A, et al. The roles of chemotherapy and surgery in gastric carcinoma and the influence of prognostic factors on survival. Am J Clin Oncol. 2000;23:53-57.
4. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
5. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy. 5th ed. American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000;88:921-932.
6. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002;94:641-646.
7. Baek JH, Kim JG, Jeon SB, et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer. 2006;94:1407-1411.
8. Papakostas R Tsavdaridis D, Kosmidis R et al. Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study. Gastric Cancer. 2006;9:26-31.
9. Jeung HC, Rha SY, Kim YT, Noh SH, Roh JK, Chung HC. A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. Oncology. 2006;70:63-70.
10. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23:5660-5667.
11. Ajani JA, Lee FC, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:663-667.
12. Park SH, Lee WK, Chung M, et al. Paclitaxel versus docetaxel for advanced gastric cancer, a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs. 2006;17:225-229.
13. Enzinger PC, Kulke MH, Clark JW, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005;50:2218-2223.
14. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005;3:49-58.
15. Rohatgi PR, Yao JC, Hess K, et al. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006;107:2576-2580.
16. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218:583-592.
17. Kim JP, Lee JH, Kim SJ, et al. Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer. Gastric Cancer. 1998;1:125-133.
18. Talamonti MS, Kim SR Yao KA, et al. Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery. 2003;134:720-727; discussion 727-729.